Tretinoin

Tretinoin is the pharmaceutical name for all-trans retinoic acid, a naturally occurring metabolite of vitamin A and the prototype of the retinoid class of drugs ^[1]. Its molecular formula is C20H28O2. First patented in the 1950s, it was developed for acne during the 1960s by dermatologists at the University of Pennsylvania and approved by the United States Food and Drug Administration for that use in 1971 ^[1]. A separate and dramatic chapter in its history came in the late 1980s, when researchers in Shanghai showed that the same molecule could drive leukemic cells to mature, reshaping the treatment of a once highly fatal cancer ^[2].

In dermatology, topical tretinoin is a mainstay treatment for acne, effective against both the inflamed pimples and the blackheads and whiteheads of comedonal acne, and it is the most thoroughly studied retinoid for reversing signs of sun-induced skin aging such as fine wrinkles and uneven pigmentation ^[1][3]. It has also been used to lighten post-inflammatory hyperpigmentation ^[3]. In oncology, an oral form is central to the treatment of acute promyelocytic leukemia, a subtype of acute myeloid leukemia defined by a specific chromosomal rearrangement; there tretinoin is used to induce remission, typically in combination with other agents rather than as long-term maintenance ^[2]. It is supplied as creams, gels, lotions, and microsphere gels for the skin and as capsules for leukemia, under brand names including Retin-A, Renova, and Vesanoid.

Tretinoin is prescription-only and available generically ^[1]. Topical use commonly causes skin irritation, redness, dryness, peeling, and increased sensitivity to sunlight, effects that often ease as treatment continues ^[1]. The oral form used in leukemia carries more serious risks, including a potentially life-threatening reaction known as differentiation syndrome, along with a rise in white blood cell counts and elevated blood fats ^[2]. A critical caution for all retinoids is pregnancy: tretinoin can cause birth defects, so its use during pregnancy is contraindicated, and the oral form in particular is strongly teratogenic.

Topically, tretinoin commonly causes dryness, peeling, redness, and heightened sun sensitivity, so it is introduced gradually and paired with sun protection. It is teratogenic and must not be used in pregnancy; the oral form used in leukemia carries serious risks (including differentiation syndrome) and is managed in hospital. Prescription medicine.

Tretinoin is used in acute promyelocytic leukemia (APL) as part of combination chemotherapy, most commonly with arsenic trioxide (ATO) as the standard induction regimen. The combination is synergistic for differentiation therapy; both all-trans retinoic acid (ATRA) and ATO modulate overlapping but distinct pathways in leukemic cell differentiation, and this rational combination achieves superior remission rates compared to either agent alone. ^{[20] [21]} Differentiation syndrome, a potentially life-threatening complication of ATRA and ATO therapy, occurs in approximately 10% of pediatric patients during induction and is predicted by female sex, non-chemotherapy treatment groups, specific BCR-ABL subtypes, and elevated peripheral promyelocyte burden; early recognition guided by these risk factors is essential to prevent mortality from pulmonary complications and coagulopathy. ^[22] Src family kinase inhibitors, particularly dasatinib, have shown promise in preclinical models as adjunctive agents that synergistically enhance ATRA-induced differentiation beyond the standard ATO combination, though this remains investigational.

Checking a whole stack? Run it through interactions + stacks.

Tretinoin, the all-trans form of retinoic acid, is a naturally occurring metabolite of vitamin A, and its therapeutic career began with dermatology. In the late 1960s the University of Pennsylvania dermatologist Albert Kligman studied it for acne, leading to United States approval of topical tretinoin, marketed as Retin-A, in 1971; over the following years Kligman and others documented that the same preparation improved the fine wrinkles, roughness, and mottling of sun-damaged skin, establishing it as a foundational anti-aging retinoid.

A very different chapter opened in the late 1980s, when researchers in Shanghai, including Wang Zhen-Yi and colleagues, showed that oral all-trans retinoic acid could drive the malignant cells of acute promyelocytic leukemia to mature into normal white blood cells rather than killing them outright, pioneering the concept of differentiation therapy and dramatically improving the prognosis of that once highly fatal cancer. The oral drug was later approved in the United States as Vesanoid in 1995. Tretinoin appears on the World Health Organization's List of Essential Medicines and is sold under numerous brand names for both skin and blood-cancer uses.

Tretinoin holds an almost singular reputation as the gold-standard topical retinoid, the ingredient against which newer anti-aging and acne treatments are routinely measured. Decades of use and study support its ability to clear acne, smooth texture, fade uneven pigmentation, and rebuild the collagen degraded by ultraviolet light, making it one of the few topical agents with genuine evidence for reversing signs of photoaging.

In oncology its standing is nothing short of historic, having helped turn acute promyelocytic leukemia from one of the deadliest leukemias into one of the most curable, all without traditional cytotoxic chemotherapy in many regimens. Users should know that the skin benefits demand patience and consistency, since an initial phase of dryness, peeling, and irritation is common before tolerance develops, and diligent sun protection is essential. That early adjustment aside, few compounds combine such a strong evidence base with such transformative effects across two entirely different fields of medicine.